In today’s episode, Neurologist, Robert M. Hutchman, MD, MDS, discusses Depression in Parkinson’s disease. Some studies indicate that anywhere from 40% to 60% of PD suffers experience clinically significant depression. Several recent research efforts have examined the efficacy of treating depression in PD with medications that approach mood stabilization differently. Some recent research is discussed that indicates depression in the Parkinson’s disease may have a different pathology that requires a different treatment approach. Tricyclic Anti-depressants (TCA), Selective Serotonin Reuptake Inhibitors (SSRI), and a relatively new class of extended release atypical anti-depressants called norepinephrine and dopamine reuptake inhibitor (NDRI) are discussed in today’s episode. As Dr. Hutchman explains, the objective is to find the best medication to treat these complex issues. Does new medical research hold the answer to better treatments? Listen and find out.